Compare TDS & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TDS | TGTX |
|---|---|---|
| Founded | 1968 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 4.9B |
| IPO Year | N/A | 2008 |
| Metric | TDS | TGTX |
|---|---|---|
| Price | $43.95 | $33.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $53.33 | $49.80 |
| AVG Volume (30 Days) | 649.7K | ★ 2.0M |
| Earning Date | 05-01-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.38% | N/A |
| EPS Growth | N/A | ★ 1746.67 |
| EPS | N/A | ★ 2.77 |
| Revenue | N/A | ★ $2,785,000.00 |
| Revenue This Year | $4.05 | $49.30 |
| Revenue Next Year | $1.72 | $24.55 |
| P/E Ratio | ★ N/A | $11.99 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $31.07 | $25.37 |
| 52 Week High | $47.80 | $46.48 |
| Indicator | TDS | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 54.72 | 67.15 |
| Support Level | $43.02 | $33.58 |
| Resistance Level | $45.02 | $37.11 |
| Average True Range (ATR) | 1.27 | 1.49 |
| MACD | 0.07 | 0.40 |
| Stochastic Oscillator | 95.89 | 92.16 |
Telephone and Data Systems Inc is a diversified telecommunications operator that provides mobile, telephone, and broadband services. The company's segments include UScellular Wireless, UScellular Towers, and TDS Telecom. It generates maximum revenue from the UScellular Wireless segment.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.